SCHEMBL2806902

SCHEMBL2806902

CCCCCCCCCCC#CCCO

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.56
HMGCR P04035 3/20 0.56
ALDH1A1 P00352 3/20 0.52
LMNA P02545 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
TSHR P16473 2/20 0.52
HSD17B10 Q99714 1/20 0.52
RECQL P46063 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
ALOX12 P18054 1/20 0.47
BLM P54132 1/20 0.47
MCL1 Q07820 1/20 0.47
SELP P16109 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2483643 1.00 PTPN7 (0.56) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL487444 1.00 PTPN7 (0.56) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL8684335 1.00 PTPN7 (0.56) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL29479496 1.00 PTPN7 (0.56) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL487538 0.97 PTPN7 (0.52) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL10959870 0.93 PTPN7 (0.50) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL10960337 0.93 PTPN7 (0.50) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL10956905 0.93 PTPN7 (0.50) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL10962163 0.93 PTPN7 (0.50) PTPN7HMGCRALDH1A1LMNAMEN1
SCHEMBL15283605 0.90 HMGCR (0.59) PTPN7HMGCRALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049099-A1 DOUBLE-STRANDED SIRNA, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF YIMEICHENGJIAN SHANGHAI BIOMEDICAL CO LTD (CN) 2026-02-19 US disclosed
CN-119241620-B Double-stranded siRNA, preparation method, pharmaceutical composition and application thereof 羿美诚健(上海)生物医药有限公司 2025-04-08 CN disclosed
CN-119241620-A Double-stranded siRNA, preparation method, pharmaceutical composition and application thereof 羿美诚健(上海)生物医药有限公司 2025-01-03 CN disclosed
EP-2396418-A1 METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEINS Genentech, Inc. (US) 2011-12-21 EP disclosed
WO-2010093916-A1 METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEINS GENENTECH, INC. (US) 2010-08-19 WO disclosed
US-20100189660-A1 METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEIN GENENTECH, INC. (US) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049099-A1 DOUBLE-STRANDED SIRNA, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF RNMT, NSUN2, RNGTT PTPN7 4052/4885HMGCR 1228/4885ALDH1A1 346/4885
US-20100189660-A1 METHODS FOR THE DETECTION OF FATTY-ACYLATED PROTEIN FABP1, DBI, FABP4 PTPN7 1870/4885HMGCR 1571/4885ALDH1A1 3098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.